Attenuation of pain and inflammation in adjuvant-induced arthritis by the proteasome inhibitor MG132

Arthritis and Rheumatism

Volumn 62, Issue 7, 2010, Pages 2160-2169

  Ahmed, Aisha S ^a   Li, Jian ^a   Ahmed, Mahmood ^a   Hua, Long ^a   Yakovleva, Tatiana ^b   Ossipov, Michael H ^c   Bakalkin, Georgy ^b   Stark, André ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CALCITONIN GENE RELATED PEPTIDE; I KAPPA B; PROTEIN P50; SUBSTANCE P;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRALGIA; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DNA BINDING; DRUG EFFECT; FEMALE; GEL MOBILITY SHIFT ASSAY; IMMUNOHISTOCHEMISTRY; JOINT DESTRUCTION; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCORING SYSTEM; SENSORY NEUROPATHY;

ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, INFECTIOUS; BIOLOGICAL MARKERS; BONE DENSITY; CALCITONIN GENE-RELATED PEPTIDE; CYSTEINE PROTEINASE INHIBITORS; DNA; FEMALE; JOINTS; LEUPEPTINS; MYCOBACTERIUM; MYCOBACTERIUM INFECTIONS; NF-KAPPA B; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; RATS; RATS, INBRED LEW; SUBSTANCE P;

EID: 77954236941     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27492     Document Type: Article

References (50)

1. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2:244-7. (Pubitemid 19180612)
2. Dayer JM. The saga of the discovery of IL-1 and TNF and their specific inhibitors in the pathogenesis and treatment of rheumatoid arthritis. Joint Bone Spine 2002;69:123-32.
3. Wahl SM, Allen JB, Hines KL, Imamichi T, Wahl AM, Furcht LT, et al. Synthetic fibronectin peptides suppress arthritis in rats by interrupting leukocyte adhesion and recruitment. J Clin Invest 1994;94:655-62. (Pubitemid 24250996)
4. Chen F, Castranova V, Shi X, Demers LM. New insights into the role of nuclear factor-κB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 1999;45:7-17. (Pubitemid 29036378)
5. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-κB. Annu Rev Cell Biol 1994;10:405-55.
6. Baldwin AS Jr. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-83.
7. DiDonato J, Mercurio F, Rosette C, Wu-Li J, Suyang H, Ghosh S, et al. Mapping of the inducible IκB phosphorylation sites that signal its ubiquitination and degradation. Mol Cell Biol 1996;16: 1295-304.
8. Okamoto H, Cujec TP, Yamanaka H, Kamatani N. Molecular aspects of rheumatoid arthritis: role of transcription factors. FEBS J 2008;275:4463-70.
9. Marok R, Winyard PG, Coumbe A, Kus ML, Gaffney K, Blades S, et al. Activation of the transcription factor nuclear factor-κB in human inflamed synovial tissue. Arthritis Rheum 1996;39:583-91. (Pubitemid 26118035)
10. Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, et al. Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci U S A 1998;95:15671-6.
11. Lorton D, Lubahn CL, Zautra AJ, Bellinger DL. Proinflammatory cytokines and sickness behavior in rheumatic diseases. Curr Pharm Des 2008;14:1242-60.
12. Levine JD, Collier DH, Basbaum AI, Moskowitz MA, Helms CA. Hypothesis: the nervous system may contribute to the pathophysiology of rheumatoid arthritis. J Rheumatol 1985;12:406-11.
13. Benrath J, Eschenfelder C, Zimmerman M, Gillardon F. Calcitonin gene-related peptide, substance P and nitric oxide are involved in cutaneous inflammation following ultraviolet irradiation. Eur J Pharmacol 1995;293:87-96.
14. Ahmed M, Bjurholm A, Schultzberg M, Theodorsson E, Kreicbergs A. Increased levels of substance P and calcitonin generelated peptide in rat adjuvant arthritis: a combined immunohistochemical and radioimmunoassay analysis. Arthritis Rheum 1995; 38:699-709.
15. Ahmed M, Bjurholm A, Srinivasan GR, Lundeberg T, Theodorsson E, Schultzberg M, et al. Capsaicin effects on substance P and CGRP in rat adjuvant arthritis. Regul Pept 1995;55:85-102.
16. Hernanz A, De Miguel E, Romera N, Perez-Ayala C, Gijon J, Arnalich F. Calcitonin gene-related peptide II, substance P and vasoactive intestinal peptide in plasma and synovial fluid from patients with inflammatory joint disease. Br J Rheumatol 1993;32: 31-5. (Pubitemid 23053588)
17. Van Tijn P, Hol EM, van Leeuwen FW, Fischer DF. The neuronal ubiquitin-proteasome system: murine models and their neurological phenotype. Prog Neurobiol 2008;85:176-93.
18. Shah IM, Di Napoli M. The ubiquitin-proteasome system and proteasome inhibitors in central nervous system diseases. Cardiovasc Hematol Disord Drug Targets 2007;7:250-73. (Pubitemid 350302901)
19. Moss A, Blackburn-Munro G, Garry EM, Blakemore JA, Dickinson T, Rosie R, et al. A role of the ubiquitin-proteasome system in neuropathic pain. J Neurosci 2002;22:1363-72. (Pubitemid 34163737)
20. Ossipov MH, Bazov I, Gardell LR, Kowal J, Yakovleva T, Usynin I, et al. Control of chronic pain by the ubiquitin proteasome system in the spinal cord. J Neurosci 2007;27:8226-37. (Pubitemid 47219620)
21. Pearson CM, Wood FD. Studies of arthritis and other lesions induced in rats by the injection of mycobacterial adjuvant. VII. Pathologic details of the arthritis and spondylitis. Am J Pathol 1963;42:73-95.
22. Larsson P, Kleinau S, Holmdahl R, Klareskog L. Homologous type II collagen-induced arthritis in rats: characterization of the disease and demonstration of clinically distinct forms of arthritis in two strains of rats after immunization with the same collagen preparation. Arthritis Rheum 1990;33:693-701. (Pubitemid 20166571)
23. Randall LO, Selitto JJ. A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther 1957;111: 409-19.
24. Ackerman NR, Rooks WH II, Shott L, Genant H, Maloney P, West E. Effects of naproxen on connective tissue changes in the adjuvant arthritic rat. Arthritis Rheum 1979;22:1365-74. (Pubitemid 10194576)
25. Bjurholm A, Kreicbergs A, Schultzberg M. Fixation and demineralization of bone tissue for immunohistochemical staining of neuropeptides. Calcif Tissue Int 1989;45:227-31. (Pubitemid 19240498)
26. Weinberger A, Halpern M, Zahalka MA, Quintana F, Traub L, Moroz C. Placental immunomodulator ferritin, a novel immunoregulator, suppresses experimental arthritis. Arthritis Rheum 2003;48:846-53. (Pubitemid 36302024)
27. Shahrara S, Proudfoot AE, Park CC, Volin MV, Haines GK, Woods JM, et al. Inhibition of monocyte chemoattractant protein-1 ameliorates rat adjuvant-induced arthritis. J Immunol 2008; 180:3447-56.
28. Bakalkin G, Yakovleva T, Terenius L. NF-κB-like factors in the murine brain: developmentally-regulated and tissue-specific expression. Brain Res Mol Brain Res 1993;20:137-46.
29. Li J, Kreicbergs A, Bergstrom J, Stark A, Ahmed M. Site-specific CGRP innervation coincides with bone formation during fracture healing and modeling: a study in rat angulated tibia. J Orthop Res 2007;25:1204-12. (Pubitemid 47365294)
30. Bakalkin G, Yakovleva T, Terenius L. Prodynorphin gene expression relates to NF-κB factors. Brain Res Mol Brain Res 1994;24: 301-12. (Pubitemid 24202867)
31. Bakalkin G, Yakovleva T, Hurd YL, Nussenzweig A, Li GC, Terenius L. Autoantigen Ku in the brain: developmentally regulated expression and subcellular localization. Neuroreport 1998;9: 2147-51.
32. Elliott PJ, Zollner TM, Boehncke WH. Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med 2003;81:235-45.
33. Saxler G, Loer F, Skumavc M, Pfortner J, Hanesch U. Localization of SP- and CGRP-immunopositive nerve fibers in the hip joint of patients with painful osteoarthritis and of patients with painless failed total hip arthroplasties. Eur J Pain 2007;11:67-74.
34. Ambalavanar R, Moritani M, Moutanni A, Gangula P, Yallampalli C, Dessem D. Deep tissue inflammation upregulates neuropeptides and evokes nociceptive behaviors which are modulated by a neuropeptide antagonist. Pain 2006;120:53-68.
35. Levine JD, Clark R, Devor M, Helms C, Moskowitz MA, Basbaum AI. Intraneuronal substance P contributes to the severity of experimental arthritis. Science 1984;226:547-9.
36. Han Z, Boyle DL, Manning AM, Firestein GS. AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 1998;28:197-208.
37. Handel ML, McMorrow LB, Gravallese EM. Nuclear factor-κB in rheumatoid synovium: localization of p50 and p65. Arthritis Rheum 1995;38:1762-70.
38. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, et al. Novel inhibitors of cytokine-induced IκBα phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 1997;272: 21096-103.
39. Magnani M, Crinelli R, Bianchi M, Antonelli A. The ubiquit-independent proteolytic system and other potential targets for the modulation of nuclear factor-κB (NF-κB). Curr Drug Targets 2000;1:387-99.
40. Soysa NS, Alles N. NF-κB functions in osteoclasts. Biochem Biophys Res Commun 2009;378:1-5.
41. Zwerina J, Hayer S, Tohidast-Akrad M, Bergmeister H, Redlich K, Feige U, et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction. Arthritis Rheum 2004;50: 277-90.
42. Pettit AR, Ji H, von Stechow D, Muller R, Goldring SR, Choi Y, et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 2001;159:1689-99.
43. Zangari M, Yaccoby S, Cavallo F, Esseltine D, Tricot G. Response to bortezomib and activation of osteoblasts in multiple myeloma. Clin Lymphoma Myeloma 2006;7:109-14.
44. Mukherjee S, Raje N, Schoonmaker JA, Liu JC, Hideshima T, Wein MN, et al. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 2008;118:491-504.
45. Wooley PH. Animal models of rheumatoid arthritis. Curr Opin Rheumatol 1991;3:407-20.
46. Cavaletti G, Gilardini A, Canta A, Rigamonti L, Rodriguez-Menendez V, Ceresa C, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 2007;204:317-25.
47. Cata JP, Weng HR, Lee BN, Reuben JM, Dougherty PM. Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol 2006; 72:151-69.
48. Berkers CR, Verdoes M, Lichtman E, Fiebiger E, Kessler BM, Anderson KC, et al. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods 2005;2:357-62. (Pubitemid 41130981)
49. Saulle E, Petronelli A, Pasquini L, Petrucci E, Mariani G, Biffoni M, et al. Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. Apoptosis 2007;12:635-55.
50. Fernandez Y, Miller TP, Denoyelle C, Esteban JA, Tang WH, Bengston AL, et al. Chemical blockage of the proteasome inhibitory function of bortezomib: impact on tumor cell death. J Biol Chem 2006;281:1107-18.